Influence of best objective response to first‐line treatment on survival outcomes in advanced urothelial carcinoma in the era of sequential therapy with enfortumab vedotin
International Journal of Urology · 2025
DOI: 10.1111/iju.15686 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Urology, 2025. Verfasst von Kohei Kobatake und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Transitional Cell, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Objective
This study evaluated whether first‐line treatment affects survival outcomes in patients with advanced urothelial carcinoma undergoing sequential therapy with chemotherapy, immune checkpoint inhibitors, and enfortumab vedotin.
Methods
This multicenter retrospective study included 57 patients treated at Hiroshima University Hospital and its affiliated institutions between 2009 and 2024. Patients received chemotherapy as a first‐line treatment (gemcitabine plus cisplatin or carboplatin), followed by second‐line immune checkpoint inhibitors (pembrolizumab or avelumab) and third‐line enfortumab vedotin. Assessed outcomes included overall survival and time to treatment failure. Cox regression analysis identified prognostic factors for overall survival.
Results
Over a median follow‐up of 20.5 months, median overall survival was not reached after first‐line treatment. Gemcitabine with cisplatin was selected in 31.6% of cases, while gemcitabine and carboplatin was chosen in 68.4% of cases as the first‐line treatment; subsequently, 66.7% received pembrolizumab, and 33.3% received avelumab in the second‐line treatment. Patients who achieved a complete or partial response with the first‐line treatment had significantly longer overall survivals from both first‐line and enfortumab vedotin initiation than those with stable or progressive disease. In cases that achieved complete or partial responses, avelumab was more frequently selected as a second‐line therapy. However, in the first‐line treatment, multivariate analysis identified only stable or progressive disease as a significant predictor of worse overall survival.
Conclusion
The best response to first‐line treatment predicted both overall survival from first‐line initiation and outcomes following enfortumab vedotin treatment, underscoring its prognostic value in sequential therapy for patients with advanced urothelial carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
- Department of Urology, Hiroshima-Nishi Medical Center, Otake City, Hiroshima, Japan.
- Department of Urology, Higashi-Hiroshima Medical Center, Higashi-Hiroshima City, Hiroshima, Japan.
- Department of Urology, Medical Corporation, JR Hiroshima Hospital, Hiroshima City, Hiroshima, Japan.
- Department of Urology, JA Hiroshima General Hospital, Hatsukaichi City, Hiroshima, Japan.
- Department of Urology, JA Onomichi General Hospital, Onomichi City, Hiroshima, Japan.
ORCID-Profile: Kohei Kobatake, Keisuke Goto, Yohei Sekino, Nobuyuki Hinata
Zitieren
APA
Kobatake, K., Goto, K., Sakamoto, Y., Iwane, K., Nishida, K., Hashimoto, K., Asami, A., Iwamoto, H., Hayashi, T., Takemoto, K., Naito, M., Miyamoto, S., Sekino, Y., Kitano, H., Goriki, A., Hieda, K., & Hinata, N. (2025). Influence of best objective response to first‐line treatment on survival outcomes in advanced urothelial carcinoma in the era of sequential therapy with enfortumab vedotin. International Journal of Urology. https://doi.org/10.1111/iju.15686
Vancouver
Kobatake K, Goto K, Sakamoto Y, Iwane K, Nishida K, Hashimoto K, et al. Influence of best objective response to first‐line treatment on survival outcomes in advanced urothelial carcinoma in the era of sequential therapy with enfortumab vedotin. International Journal of Urology. 2025. doi:10.1111/iju.15686
BibTeX
@article{Kobatake2025,
author = {Kobatake, Kohei and Goto, Keisuke and Sakamoto, Yuki and Iwane, Kyohsuke and Nishida, Kensuke and Hashimoto, Kunihiro and Asami, Akihiro and Iwamoto, Hideo and Hayashi, Tetsutaro and Takemoto, Kenshiro and Naito, Miki and Miyamoto, Shunsuke and Sekino, Yohei and Kitano, Hiroyuki and Goriki, Akihiro and Hieda, Keisuke and Hinata, Nobuyuki},
title = {Influence of best objective response to first‐line treatment on survival outcomes in advanced urothelial carcinoma in the era of sequential therapy with enfortumab vedotin},
journal = {International Journal of Urology},
year = {2025},
doi = {10.1111/iju.15686}
}
EUVIMED